What kinds of cancer can TRAZIMERA help to treat?

INDICATIONS

Adjuvant Breast Cancer

TRAZIMERA is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* TRAZIMERA can be used in several different ways:

  • As part of a treatment course that includes the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel

  • With the chemotherapy drugs docetaxel and carboplatin

  • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)

Patients are selected for therapy based on an FDA-approved test for trastuzumab products.

*High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

 

Metastatic Breast Cancer

TRAZIMERA has 2 approved uses in metastatic breast cancer:

  • TRAZIMERA, in combination with the chemotherapy drug paclitaxel, is approved for the first-line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer

  • TRAZIMERA alone is approved for the treatment of HER2+ breast cancer in patients who have received one or more chemotherapy courses for metastatic disease

Patients are selected for therapy based on an FDA-approved test for trastuzumab products.

 

Metastatic Gastric Cancer

TRAZIMERA is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.

Patients are selected for therapy based on an FDA-approved test for trastuzumab products.